Search results

15 items matching your search terms.
Filter the results.
Item type













New items since



Sort by relevance · date (newest first) · alphabetically
Potential pancreatic cancer treatment could increase life expectancy
Device that drives drugs into solid tumors that are poorly vascularized opens the possibility of life-saving surgeries in cancer patients.
Located in News
Channing Der presents lecture at Pancreatic Cancer Action Network
Der highlighted recent research findings that have stimulated new experimental directions for improve therapies for pancreatic cancer.
Located in News
Der receives grant funding for pancreatic cancer research
Channing Der, PhD, Sarah Graham Kenan Professor of Pharmacology, received a two-year $200,000 American Association for Cancer Research Innovative grant from the Pancreatic Cancer Action Network. His grant will fund research on the mechanism of ERK inhibition resistance and ERK-dependent pancreatic cancer.
Located in News / 2012 News
USA Today looks at pancreatic cancer, Goldberg quoted
Richard Goldberg, MD, physician-in-chief of the N.C. Cancer Hospital, is quoted in the Health section of USA Today's website.
Located in News / 2011 News
Located in Newsroom / UNC Lineberger in the News
Located in Newsroom / UNC Lineberger in the News
Located in Newsroom / UNC Lineberger in the News
Trainee Kirsten Bryant Awarded AACR Pathway to Leadership Grant
The Pancreatic Cancer Action Network-AACR Pathway to Leadership Grant represents a joint effort to ensure the future leadership of pancreatic cancer research by supporting outstanding early career investigators beginning in their postdoctoral research positions and continuing through their successful transition to independence.
Located in ITCMS News
Device hits pancreatic tumors hard with toxic four-drug cocktail, sparing the body
A new implantable device delivers first-line treatment for pancreatic cancer directly to tumors, bypassing bloodstream and limiting widespread side effects. A team of researchers from the University of North Carolina including Drs. Jen Jen Yeh and Joseph DeSimone, has shown in preclinical research that the device can deliver a particularly toxic dose of drugs directly to pancreatic tumors to stunt their growth or, in some cases, shrink them. This approach would also spare the patient toxic side effects.
Located in News
Preclinical study finds no benefit for diabetes drug in pancreatic cancer
UNC Lineberger researchers found in a study published in PLOS ONE that the diabetes drug metformin failed to show any benefit against pancreatic cancer, despite excitement about the drug for potential anti-cancer benefits. They believe the study shows the importance of testing new therapies in preclinical animal models that incorporate actual tumor tissue to better predict patient response.
Located in News